MX2018011413A - Metodos para tratar y prevenir infeccion por c. difficile. - Google Patents

Metodos para tratar y prevenir infeccion por c. difficile.

Info

Publication number
MX2018011413A
MX2018011413A MX2018011413A MX2018011413A MX2018011413A MX 2018011413 A MX2018011413 A MX 2018011413A MX 2018011413 A MX2018011413 A MX 2018011413A MX 2018011413 A MX2018011413 A MX 2018011413A MX 2018011413 A MX2018011413 A MX 2018011413A
Authority
MX
Mexico
Prior art keywords
treating
preventing
methods
difficile infection
difficile
Prior art date
Application number
MX2018011413A
Other languages
English (en)
Inventor
P Draper Michael
Ken Tanaka S
Original Assignee
Paratek Pharm Innc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paratek Pharm Innc filed Critical Paratek Pharm Innc
Publication of MX2018011413A publication Critical patent/MX2018011413A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen métodos para tratar o prevenir infección causada por C. difficile y las afecciones patológicas asociadas, relacionadas con infección por C. difficile.
MX2018011413A 2016-03-24 2017-03-24 Metodos para tratar y prevenir infeccion por c. difficile. MX2018011413A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662312996P 2016-03-24 2016-03-24
US201662320053P 2016-04-08 2016-04-08
PCT/US2017/023958 WO2017165729A1 (en) 2016-03-24 2017-03-24 Methods for treating and preventing c. difficile infection

Publications (1)

Publication Number Publication Date
MX2018011413A true MX2018011413A (es) 2019-01-10

Family

ID=59900751

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018011413A MX2018011413A (es) 2016-03-24 2017-03-24 Metodos para tratar y prevenir infeccion por c. difficile.
MX2023004969A MX2023004969A (es) 2016-03-24 2018-09-20 Metodos para tratar y prevenir infeccion por c. difficile.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023004969A MX2023004969A (es) 2016-03-24 2018-09-20 Metodos para tratar y prevenir infeccion por c. difficile.

Country Status (13)

Country Link
US (2) US20170319603A1 (es)
EP (1) EP3432891A4 (es)
JP (3) JP7458706B2 (es)
CN (1) CN109152789A (es)
AU (2) AU2017238644B2 (es)
BR (2) BR122024000249A2 (es)
CA (1) CA3018872A1 (es)
MX (2) MX2018011413A (es)
MY (1) MY197627A (es)
PH (1) PH12018502020A1 (es)
RU (1) RU2751509C1 (es)
SG (2) SG10201913559VA (es)
WO (1) WO2017165729A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122024000249A2 (pt) * 2016-03-24 2024-02-27 Paratek Pharmaceuticals, Inc. Uso de um composto ou um sal do mesmo
TW202206081A (zh) * 2016-08-03 2022-02-16 美商派瑞泰Ｓｐｖ２有限公司 ９—胺甲基米諾四環素化合物及其用途
SG10201913599RA (en) * 2016-11-01 2020-02-27 Paratek Pharm Innc 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (cabp)
JP7110562B2 (ja) * 2017-09-06 2022-08-02 株式会社三洋物産 遊技機
JP7110563B2 (ja) * 2017-09-06 2022-08-02 株式会社三洋物産 遊技機
JP7110560B2 (ja) * 2017-09-06 2022-08-02 株式会社三洋物産 遊技機
EP3846805A4 (en) * 2018-09-04 2022-08-24 Paratek Pharmaceuticals, Inc. METHODS OF TREATING MYCOBACTERIAL INFECTIONS USING TETRACYCLINE COMPOUNDS
KR20210073531A (ko) * 2018-10-10 2021-06-18 누트리 컴퍼니 리미티드 클로스트리디움 디피실균 감염증의 예방 및/또는 치료제
EP4165016A1 (en) * 2020-06-11 2023-04-19 Paratek Pharmaceuticals, Inc. Crystalline forms of omadacycline, methods of synthesis thereof and methods of use thereof
PT117254B (pt) 2021-05-26 2024-04-18 Hovione Farm S A Método de síntese de compostos 9-aminometil tetraciclinas

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2324392A (en) * 1991-07-24 1993-02-23 Procter & Gamble Company, The Antimicrobial treatment methods and compositions
SI1301467T1 (sl) * 2000-07-07 2007-02-28 Tufts College 9-substituirane minociklinske spojine
US7553828B2 (en) * 2001-03-13 2009-06-30 Paratek Pharmaceuticals, Inc. 9-aminomethyl substituted minocycline compounds
EP2332549A1 (en) * 2001-07-13 2011-06-15 Paratek Pharmaceuticals, Inc. Novel tetracyclines and their use in medicine
JP2009521456A (ja) * 2005-12-22 2009-06-04 ワイス チゲサイクリンでの胃腸管感染症の治療法
CA2639406A1 (en) * 2006-01-24 2007-08-02 Paratek Pharmaceuticals, Inc. Methods of increasing oral bioavailability of tetracyclines
TW202332671A (zh) * 2008-05-23 2023-08-16 美商Ｐｒｔｋ Ｓｐｖ２公司 四環素化合物之甲苯磺酸鹽及同素異形體
BRPI1008058A8 (pt) * 2009-02-11 2018-03-27 Cedars Sinai Medical Center uso de antibióticos para reduzir a probabilidade de desenvolver síndrome do intestino irritável pós-infecciosa
ES2757675T3 (es) * 2010-04-15 2020-04-29 Progenics Pharm Inc Anticuerpos para el tratamiento de la infección y enfermedad asociada a Clostridium difficile
WO2012050826A1 (en) * 2010-09-29 2012-04-19 St. Jude Children's Research Hostpital Methods for treating clostridium difficile infections
WO2012065028A2 (en) * 2010-11-11 2012-05-18 Concert Pharmaceuticals Inc. Substituted tetracyclines
CN105451561A (zh) * 2013-02-04 2016-03-30 赛里斯治疗公司 组合物和方法
US20140274800A1 (en) * 2013-03-13 2014-09-18 Procarta Biosystems Ltd. Transcription factor decoys for the treatment and prevention of infections caused by bacteria including clostridium difficile
BR122024000249A2 (pt) * 2016-03-24 2024-02-27 Paratek Pharmaceuticals, Inc. Uso de um composto ou um sal do mesmo

Also Published As

Publication number Publication date
CA3018872A1 (en) 2017-09-28
JP2019509318A (ja) 2019-04-04
BR112018069303A2 (pt) 2019-01-22
AU2017238644B2 (en) 2022-12-15
RU2751509C1 (ru) 2021-07-14
AU2017238644A1 (en) 2018-10-25
EP3432891A1 (en) 2019-01-30
JP2022115985A (ja) 2022-08-09
EP3432891A4 (en) 2019-10-30
US20170319603A1 (en) 2017-11-09
WO2017165729A1 (en) 2017-09-28
PH12018502020A1 (en) 2019-07-15
SG11201808246SA (en) 2018-10-30
SG10201913559VA (en) 2020-02-27
US20200281948A1 (en) 2020-09-10
AU2023200798A1 (en) 2023-03-09
JP2024023187A (ja) 2024-02-21
CN109152789A (zh) 2019-01-04
MX2023004969A (es) 2023-05-24
BR122024000249A2 (pt) 2024-02-27
JP7458706B2 (ja) 2024-04-01
MY197627A (en) 2023-06-29

Similar Documents

Publication Publication Date Title
PH12018502020A1 (en) Methods for treating and preventing c. difficile infection
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
PH12018501378A1 (en) Compositions and methods for the treatment of hemoglobinopathies
MX2017001587A (es) Terapia de combinacion para tratar un paramixovirus.
MX2022016566A (es) Composiciones que comprenden una caseina y metodos para producir las mismas.
ZA201905902B (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
AU2019268074A1 (en) Methods for treating hepcidin-mediated disorders
WO2015117081A3 (en) Methods and compositions for treatment of a beta thalessemia
GB2541571A (en) Pharmaceutical compositions
EP3538189A4 (en) COMPOSITIONS, DEVICES AND METHODS FOR TREATING OPIOID RECEPTOR-MEDIATED STATES
MX2017016114A (es) Metodos para tratar o prevenir una proteopatia.
MA40457A (fr) Combinaison de médicaments pour traiter le myélome multiple
MX2017012553A (es) Compuestos espirociclicos.
WO2017096303A3 (en) Cerdulatinib for treating hematological cancers
HK1244211A1 (zh) 治療、預防或降低皮膚感染風險的方法
PH12017500602A1 (en) Methods for treating ocular conditions
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
SG10201908248PA (en) Processes for preparing fluoroketolides
JO3541B1 (ar) علاجات طبية قائمة على اناموريلين
MX2022007955A (es) Regimenes de dosificacion de erdafitinib.
EP3283103A4 (en) Methods for treating clostridium difficile infection and associated disease
ZA202002391B (en) Plant treatment
AU2017904511A0 (en) Plant treatment
PT3580211T (pt) 2-heteroaril-3-oxo-2,3-di-hidropiridazina-4-carboxamidas para o tratamento de cancro
UA99992U (ru) 2-оксо-4-фенил-5-циано-1,2,3,4-тетрагидропиридин-6-тиолат n-метилморфолиния